Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4797955
Max Phase: Preclinical
Molecular Formula: C26H32ClN7O3
Molecular Weight: 526.04
Molecule Type: Unknown
Associated Items:
ID: ALA4797955
Max Phase: Preclinical
Molecular Formula: C26H32ClN7O3
Molecular Weight: 526.04
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCCOC(=O)N1CCN(C(=O)c2nc(Nc3cc(C4CC4)[nH]n3)c3cc(Cl)ccc3n2)C[C@H]1C
Standard InChI: InChI=1S/C26H32ClN7O3/c1-3-4-5-12-37-26(36)34-11-10-33(15-16(34)2)25(35)24-28-20-9-8-18(27)13-19(20)23(30-24)29-22-14-21(31-32-22)17-6-7-17/h8-9,13-14,16-17H,3-7,10-12,15H2,1-2H3,(H2,28,29,30,31,32)/t16-/m1/s1
Standard InChI Key: KPZXPSWJTJVNFX-MRXNPFEDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 526.04 | Molecular Weight (Monoisotopic): 525.2255 | AlogP: 5.10 | #Rotatable Bonds: 8 |
Polar Surface Area: 116.34 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 10 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.18 | CX Basic pKa: 2.97 | CX LogP: 5.20 | CX LogD: 5.20 |
Aromatic Rings: 3 | Heavy Atoms: 37 | QED Weighted: 0.39 | Np Likeness Score: -1.32 |
1. Guo J,Wang T,Wu T,Zhang K,Yin W,Zhu M,Pang Y,Hao C,He Z,Cheng M,Liu Y,Zheng J,Gu J,Zhao D. (2020) Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor., 186 [PMID:31757524] [10.1016/j.ejmech.2019.111878] |
Source(1):